{
  "docId": "019de070-3f4a-73d8-b295-3b15c76ba522",
  "docSlug": "bc1fcb576f82bf5c3541f439604f314c",
  "documentTitle": "Kymera | IPO Presentation Deck | 49 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 49,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a two-column list format with icons to highlight six core investment pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3f4a-73d8-b295-3b15c76ba522/4",
  "deckHref": "/decks/019de070-3f4a-73d8-b295-3b15c76ba522",
  "deckJsonHref": "/decks/019de070-3f4a-73d8-b295-3b15c76ba522.json",
  "deckAnchorHref": "/decks/019de070-3f4a-73d8-b295-3b15c76ba522#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.32,
        "x": 0.14,
        "y": 0.25
      },
      "kind": "list",
      "text": "Mission to discover, develop & commercialize transformative therapies using targeted protein degradation (TPD)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "172c177d-3071-4e0f-9459-bb10ef4591bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.32,
        "x": 0.14,
        "y": 0.45
      },
      "kind": "list",
      "text": "Leading targeted protein degradation platform investing in unique capabilities of our proprietary discovery platform, Pegasus",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fc68c91-90b0-4c42-b382-297454aa4bcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.32,
        "x": 0.54,
        "y": 0.65
      },
      "kind": "list",
      "text": "Experienced management team of leading scientific innovators",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9cab309d-5870-40c3-a8bd-49ab7ab13337",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.32,
        "x": 0.54,
        "y": 0.25
      },
      "kind": "list",
      "text": "Robust internal pipeline focused on Oncology and Immunology with three programs projected to enter the clinic in 2021: IRAK4, IRAKIMiD and STAT3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c17d746e-c833-45c2-8838-f0ba3b636e5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.32,
        "x": 0.14,
        "y": 0.65
      },
      "kind": "list",
      "text": "Focus on un-drugged or inadequately-drugged targets in clinically validated biological pathways that TPD can potentially unlock",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8544cdf-e484-49e0-a2c4-1e7ca76ecb96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.32,
        "x": 0.54,
        "y": 0.45
      },
      "kind": "list",
      "text": "Leveraging synergies in biopharma collaborations with Vertex and Sanofi to date, to increase disease and patient impact",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb7648f9-58db-4605-aece-e42095e98d2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.24,
        "x": 0.38,
        "y": 0.05
      },
      "kind": "title",
      "text": "Investment Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b65f7753-2c85-4363-b75e-cbcf501c3c8c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "01822a68-97bf-4ea9-829f-893115f5316f",
      "evidence": "list/bullet: Robust internal pipeline focused on Oncology and Immunology with three programs projected to enter the clinic in 2021: IRAK4, IRAKIMiD and STAT3",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}